Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
629 stopped studies mapped to Malignant Hepatobiliary Neoplasm and descendants · 92% state a reason
Over the 629 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05041335 | Wet Heparinized Suction for Abdominal Cancer(EUS Heparin) | N/A | withdrawn | Sep 13, 2021 | H. Lee Moffitt Cancer Center and Research Institute | study no longer proceeding | Other (stated, no rule matched) |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… | Phase 2 | suspended | Sep 22, 2023 | National Cancer Institute (NCI) | Other - evaluation of patients on first stage | Other (stated, no rule matched) |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in… | Phase 1 | terminated | Oct 23, 2023 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | Early Phase 1 | terminated | Oct 23, 2020 | Koo Foundation Sun Yat-Sen Cancer Center | The decision has been made to terminate the study due to logistical reasons and not due to any… | Safety / toxicity |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Jun 28, 2022 | T-ACE Medical Co., Ltd | T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug… | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in…(FIGHT-302) | Phase 3 | terminated | Sep 4, 2018 | Incyte Corporation | The study was terminated due to lack of enrollment resulting from a change in the standard of care… | Safety / toxicity |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver… | Phase 1 / Phase 2 | terminated | Oct 4, 2018 | Edward Kim | Funding source decision to terminate study. | Funding |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable… | Phase 3 | terminated | Jul 25, 2014 | NRG Oncology | not stated | Not stated |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial…(HOLMBRAVE) | N/A | terminated | Jan 31, 2023 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities | Safety / toxicity |
| NCT07369791 | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced…(NOBLE) | Phase 2 | withdrawn | Jan 27, 2026 | National Health Research Institutes, Taiwan | The study was terminated due to administrative reasons following the cancellation of collaboration… | Other (stated, no rule matched) |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With… | Phase 2 | terminated | Feb 5, 2020 | OHSU Knight Cancer Institute | change in standard-of-care systemic therapy | Other (stated, no rule matched) |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and… | Phase 2 | suspended | May 8, 2024 | Tianjin Medical University Cancer Institute and Hospital | Mid-term data analysis for the project has been completed; enrollment is now suspended. | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in… | — | terminated | Oct 10, 2016 | University of Aberdeen | The project did not progress as there were no findings available for the lab analysis of microRNA… | Other (stated, no rule matched) |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed… | Phase 2 | terminated | Aug 30, 2021 | University of Cincinnati | The study is closing due to low enrollment and feasibility of the study. | Enrollment / accrual |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | — | terminated | Sep 20, 2016 | Mayo Clinic | Ran out of funds | Funding |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT05718882 | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | N/A | terminated | Feb 8, 2023 | RenJi Hospital | The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg,… | Safety / toxicity |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | Phase 2 | terminated | Nov 2, 2021 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT04107766 | NOLA (NeuWave Observational Liver Ablation) Registry | — | terminated | Sep 27, 2019 | Ethicon, Inc. | Change in Company Strategy | Sponsor / business decision |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | N/A | withdrawn | Aug 19, 2016 | Thomas Jefferson University | Principal Investigator let the institution prior to study initiation. | Investigator |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial…(LIDA-BII) | Phase 2 | terminated | Nov 1, 2018 | University Hospital, Montpellier | Enrollement rythm low, funding body decision. | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | — | withdrawn | Feb 15, 2022 | Methodist Health System | Resources | Other (stated, no rule matched) |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word… | N/A | terminated | May 8, 2015 | Centre Oscar Lambret | Lack of patient enrollment | Enrollment / accrual |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | Phase 3 | terminated | Mar 2, 2021 | Translational Research in Oncology | The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve… | Enrollment / accrual |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With…(MAST) | Phase 1 | terminated | Apr 26, 2022 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Phase 2 | terminated | Mar 31, 2020 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 | withdrawn | Jan 22, 2024 | University of Florida | funding terminated | Funding |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With… | Phase 2 | terminated | Feb 28, 2025 | Guangxi Medical University | The support from the relevant company was not obtained as planned | Sponsor / business decision |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT04258566 | Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies | N/A | terminated | Feb 6, 2020 | National Institutes of Health Clinical Center (CC) | Recruitment difficulty | Enrollment / accrual |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials